Viking Therapeutics Inc (VKTX) concluded trading on Wednesday at a closing price of $38.28, with 13.0 million shares of worth about $497.68 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -24.09% during that period and on December 18, 2024 the price saw a loss of about -18.03%. Currently the company’s common shares owned by public are about 111.43M shares, out of which, 108.05M shares are available for trading.
Stock saw a price change of -22.21% in past 5 days and over the past one month there was a price change of -22.05%. Year-to-date (YTD), VKTX shares are showing a performance of 105.70% which increased to 99.69% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $17.23 but also hit the highest price of $99.41 during that period. The average intraday trading volume for Viking Therapeutics Inc shares is 4.06 million. The stock is currently trading -23.20% below its 20-day simple moving average (SMA20), while that difference is down -34.71% for SMA50 and it goes to -38.38% lower than SMA200.
Viking Therapeutics Inc (NASDAQ: VKTX) currently have 111.43M outstanding shares and institutions hold larger chunk of about 73.78% of that.
The stock has a current market capitalization of $4.27B and its 3Y-monthly beta is at 0.89. It has posted earnings per share of -$0.94 in the same period. It has Quick Ratio of 36.47 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VKTX, volatility over the week remained 6.43% while standing at 5.41% over the month.
Stock’s fiscal year EPS is expected to drop by -5.81% while it is estimated to decrease by -53.27% in next year. EPS is likely to grow at an annualized rate of 40.00% for next 5-years, compared to annual growth of -18.89% made by the stock over the past 5-years.
Coverage by B. Riley Securities stated Viking Therapeutics Inc (VKTX) stock as a Buy in their note to investors on November 22, 2024, suggesting a price target of $109 for the stock. On November 04, 2024, H.C. Wainwright Reiterated their recommendations, while on September 11, 2024, JP Morgan Initiated their ratings for the stock with a price target of $80. Stock get an Overweight rating from Morgan Stanley on June 27, 2024.
